动态增强MRI评估人表皮生长因子受体2阳性乳腺癌靶向治疗后病理完全缓解
该回顾性分析纳入51例接受HER2靶向治疗前后均行乳腺MRI的HER2阳性乳腺癌患者,评估初始强化率、肿瘤退缩模式和DCE-MRI特征与病理完全缓解的关系。56.9%(29/51)患者达到pCR,向心性退缩模式与pCR相关(p=0.001,AUC 0.778),而RECIST定义的影像学反应、初始强化率及病灶大小与pCR无关联。
要点
- 向心性肿瘤退缩模式与pCR相关,AUC 0.778,特异度96.6%、敏感度59.1%、准确率80.4%。
- RECIST定义的影像学反应与pCR无显著关联(p=0.169)。
- 初始强化率与pCR无关联,但与腋窝转移及ki-67相关。
核心结论
- HER2阳性肿瘤靶向治疗后的退缩模式可能与pCR相关,初始强化率与pCR无关联。
研究设计与样本
- 经机构审查委员会批准的回顾性分析,纳入51例HER2阳性乳腺癌患者,分析HER2靶向治疗前后乳腺MRI。
关键影像表现/征象
- 向心性肿瘤退缩模式与pCR相关(p=0.001,AUC 0.778)。
- RECIST定义的影像学反应与pCR无显著关联(p=0.169)。
- 初始强化率与pCR无关联(阅片者1 p=0.665,阅片者2 p=0.766)。
- 病灶大小与pCR无关联(p=0.69)。
诊断标准与关键数值
- 向心性退缩模式预测pCR:AUC 0.778,准确率80.4%,特异度96.6%,敏感度59.1%。
- 初始强化率定义为首次增强后影像相对于基线的初始强化百分比。
临床应用与阅片要点
- 阅片时可关注肿瘤退缩模式,向心性退缩对pCR有较高特异度但敏感度中等。
- RECIST定义的影像学反应与pCR无显著关联,评估时需结合退缩模式。
- 初始强化率与pCR无关联,但与腋窝转移相关(阅片者1 p=0.016,阅片者2 <0.001)。
局限性
- 原文为回顾性分析。
- 作者提出未来研究评估退缩模式与纹理放射组学的相关性是有意义的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Pathologic complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after HER2-targeted therapy correlates increased disease-free survival and decreased mastectomy rates. The aim of this study was to explore tumor shrinkage patterns and initial tumor enhancement with pCR in HER2-positive breast cancer.
MATERIALS AND METHODS: This was an institutional review board-approved retrospective analysis of 51 HER2 positive breast cancer patients with breast MRI both pre- and post-HER2-targeted therapy. Initial enhancement ratio (IER, initial enhancement percentage over baseline at first postcontrast imaging), pattern of tumor shrinkage, and Dynamic contrast enhanced (DCE)-MRI imaging features were assessed. Wilcoxon rank, Spearman correlation, Fisher's exact, and Mann-Whitney tests were used to correlate MRI imaging features with pCR. IER reader agreement was evaluated by intraclass correlation. Binary logistic regression was used to evaluate multivariate associations with pCR.
RESULTS: 56.9% (29/51) of patients had pCR at surgery. Concentric tumor shrinkage pattern was associated with pCR (p = 0.001, Area under the curve (AUC) 0.778): accuracy 80.4%, specificity 96.6%, and sensitivity of 59.1%. There was no association with pCR and imaging response as defined by RECIST criteria (p = 0.169), pretreatment IER (Reader 1 (R1) p = 0.665, Reader 2 (R2) p = 0.766), or lesion size (p = 0.69). IER was associated with axillary metastases (R1 p = 0.016, R2 < 0.001) and ki-67 (R1 r = 0.52, p = 0.008, R2 r = -0.44, p = 0.028).
CONCLUSION: The shrinkage pattern of HER2-positive tumors after targeted therapy may be associated with pCR. There was no association between IER and pCR. Future studies evaluating the correlation of shrinkage patterns to texture radiomics are of interest.
引用
- Heacock L, Lewin A, Ayoola A, et al. Dynamic Contrast-Enhanced MRI Evaluation of Pathologic Complete Response in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After HER2-Targeted Therapy. Acad Radiol. 2019. PMID: 31444111. doi:10.1016/j.acra.2019.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。